{"id":972078,"date":"2026-06-15T08:50:16","date_gmt":"2026-06-15T12:50:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/"},"modified":"2026-06-15T08:50:16","modified_gmt":"2026-06-15T12:50:16","slug":"elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/","title":{"rendered":"Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>TruCan Ultra Lyme-L4\u00a0is the first and only 1\/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose<\/li>\n<li>By combining two injections into one, the vaccine minimizes &#8220;pokes&#8221; supporting comfortable wellness visits for pets<\/li>\n<li>Features proprietary\u00a0PureFil\u2122 Technology, designed to reduce vaccination reactions associated with unwanted protein<sup>i<\/sup><sup>,<\/sup><sup>ii<\/sup><sup>,<\/sup><sup>iii<\/sup><\/li>\n<li>Product expected to begin shipping in the next 30 days<\/li>\n<\/ul>\n<p>\n        <span class=\"legendSpanClass\">INDIANAPOLIS<\/span>, <span class=\"legendSpanClass\">June 15, 2026<\/span> \/PRNewswire\/ &#8212; Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) approval of\u00a0TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vaccines. This milestone marks the introduction of the first and only 1\/2 mL combination vaccine designed to protect dogs against both Lyme disease and leptospirosis, two increasingly prevalent threats to canine health.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS653209\/Elanco_Logo.jpg?id=OA2702648\" title=\"Elanco logo\" alt=\"Elanco logo\" \/>\n        <\/p>\n<\/p><\/div>\n<p>As an expansion of the\u00a0TruCan Ultra\u00a0line, this new 1\/2 mL formulation provides the same broad protection as the category-exclusive 1 mL version but in half the volume. This combination formulation allows veterinarians to provide essential protection without the need for multiple injections.<\/p>\n<p>TruCan Ultra Lyme-L4\u00a0is engineered with Elanco&#8217;s proprietary\u00a0PureFil<sup>TM<\/sup> Technology, designed to reduce vaccination reactions associated with unwanted protein, allowing clinicians to support patient comfort without compromising on protection.<sup>i,ii,iii<\/sup><\/p>\n<p>&#8220;USDA approval of TruCan Ultra Lyme-L4 is a testament to our commitment to vaccine innovation,&#8221; said Bobby\u00a0Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. &#8220;By offering a low-volume, highly-purified combination vaccine, we are providing veterinarians with a powerful tool to help close critical protection gaps while encouraging a comfortable, low-stress experience.&#8221;<\/p>\n<p>This approval comes at a critical time for canine wellness as all dogs are at risk for leptospirosis regardless of breed, size, lifestyle, or geographic location.<sup>iv<\/sup>\u00a0Leptospirosis is now recognized as a core vaccine per American Animal Hospital Association (AAHA) guidelines,<sup>v<\/sup>\u00a0meaning all dogs should be vaccinated. Additionally, the risk of Lyme disease is spreading to new geographies; however, recent data show a significant &#8220;protection gap,&#8221; with over 40% of at-risk dogs in endemic states lacking a current Lyme vaccine, despite having received their core vaccines.<sup>vi<\/sup><\/p>\n<p>&#8220;Leptospirosis and Lyme disease remain important infectious threats for dogs in the U.S.,&#8221; says Dr. Jessica Pritchard, Clinical Assistant Professor in Small Animal Internal Medicine at the University of Wisconsin-Madison School of Veterinary Medicine, &#8220;Leptospirosis vaccination is now considered core for dogs because the exposure risk exists nationwide, including in suburban and urban environments. Vaccination, along with risk-based lifestyle discussions between veterinarians and pet owners, plays an important role in protecting dogs from these preventable diseases.&#8221;<\/p>\n<p>TruCan Ultra Lyme vaccines have demonstrated 92.2% efficacy against natural infection in highly endemic areas<sup>vii<\/sup> and 100% efficacy in laboratory studies.<sup>viii<\/sup>\u00a0By reducing the number of injections required\u2014one &#8220;poke&#8221; versus two\u2014the combination vaccine is designed to improve the overall wellness visit for pets, owners and veterinary staff.<\/p>\n<p>This approval follows recent USDA approvals of\u00a0TruCan Ultra B (Oral), the first 1\/2 mL oral Bordetella vaccine, and\u00a0TruCan Ultra CIV H3N2\/H3N8, the only 1\/2 mL bivalent canine influenza vaccine. Together, these advancements add to a comprehensive suite of low-volume, highly purified vaccines that allow veterinary teams to tailor immunization protocols to the specific needs of every dog.<\/p>\n<p>TruCan Ultra Lyme-L4 is expected to begin shipping in the next 30 days. To learn more about TruCan Ultra Lyme-L4 visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710438-1&amp;h=3775224208&amp;u=https%3A%2F%2Fmy.elanco.com%2Fus%2Ftrucan&amp;a=https%3A%2F%2Fmy.elanco.com%2Fus%2Ftrucan\" target=\"_blank\" rel=\"nofollow\">https:\/\/my.elanco.com\/us\/trucan<\/a>.<\/p>\n<p>\n        <b>PM-US-26-1076<\/b>\n      <\/p>\n<p>TruCan, PureFil, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates<br \/>\u00a9 2026 Elanco or its affiliates.<\/p>\n<p>\n        <b>ABOUT ELANCO<\/b><br \/>\n        <br \/>Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose \u2013 all to Go Beyond for Animals, Customers, Society and Our People. Learn more at\u00a0<a href=\"http:\/\/www.elanco.com\" rel=\"nofollow\">www.elanco.com<\/a>.<\/p>\n<p>\n        <sup>i<\/sup>\u00a0Elanco Animal Health. Data on File. REF-29478<br \/><sup>ii<\/sup>\u00a0Franco J, Aryal UK, HogenEsch H, Moore GE. Proteomic analysis of canine vaccines. Am J Vet Res. 2023;84(3):ajvr.22.11.0192. Published 2023 Jan 24. doi:10.2460\/ajvr.22.11.0192<br \/><sup>iii<\/sup>\u00a0Ohmori K, Masuda K, Maeda S, et al. IgE reactivity to vaccine components in dogs that developed immediate type allergic reactions after vaccination. Vet Immunol Immunopathol. 2005;104(3\u20134):249\u2013256. doi:10.1016\/j.vetimm.2004.12.003<br \/><sup>iv<\/sup>\u00a0Sykes JE, Francey T, Schuller S, Stoddard RA, Cowgill LD, Moore GE. Updated ACVIM consensus statement on leptospirosis in dogs. J Vet Intern Med. 2023 Nov-Dec;37(6):1966-1982. doi: 10.1111\/jvim.16903<br \/><sup>v<\/sup>\u00a0AAHA Guidelines <br \/><sup>vi<\/sup>\u00a0Malter KB, et al. Vaccine 2022<br \/><sup>vii<\/sup>\u00a0Levy SA. Vet Ther 2002<br \/><sup>viii<\/sup>\u00a0Elanco Data on File. REF-04031\u00a0<\/p>\n<p>Investor Contact: Tiffany Kanaga (765) 740-0314 <a href=\"mailto:tiffany.kanaga@elancoah.com\" target=\"_blank\" rel=\"nofollow\">tiffany.kanaga@elancoah.com<\/a><br \/>Media Contact: Season Solorio (765) 316-0233 <a href=\"mailto:season.solorio@elancoah.com\" target=\"_blank\" rel=\"nofollow\">season.solorio@elancoah.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=DE82588&amp;sd=2026-06-15\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-12-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs-302800250.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-12-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs-302800250.html<\/a><\/p>\n<p>SOURCE Elanco Animal Health<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DE82588&amp;Transmission_Id=202606150847PR_NEWS_USPR_____DE82588&amp;DateId=20260615\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire TruCan Ultra Lyme-L4\u00a0is the first and only 1\/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine minimizes &#8220;pokes&#8221; supporting comfortable wellness visits for pets Features proprietary\u00a0PureFil\u2122 Technology, designed to reduce vaccination reactions associated with unwanted proteini,ii,iii Product expected to begin shipping in the next 30 days INDIANAPOLIS, June 15, 2026 \/PRNewswire\/ &#8212; Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) approval of\u00a0TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vaccines. This milestone marks the introduction of the first and only 1\/2 mL combination vaccine designed to protect dogs against both Lyme &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-972078","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire TruCan Ultra Lyme-L4\u00a0is the first and only 1\/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine minimizes &#8220;pokes&#8221; supporting comfortable wellness visits for pets Features proprietary\u00a0PureFil\u2122 Technology, designed to reduce vaccination reactions associated with unwanted proteini,ii,iii Product expected to begin shipping in the next 30 days INDIANAPOLIS, June 15, 2026 \/PRNewswire\/ &#8212; Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) approval of\u00a0TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vaccines. This milestone marks the introduction of the first and only 1\/2 mL combination vaccine designed to protect dogs against both Lyme &hellip; Continue reading &quot;Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T12:50:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS653209\/Elanco_Logo.jpg?id=OA2702648\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\\\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs\",\"datePublished\":\"2026-06-15T12:50:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\\\/\"},\"wordCount\":868,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS653209\\\/Elanco_Logo.jpg?id=OA2702648\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\\\/\",\"name\":\"Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\\\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS653209\\\/Elanco_Logo.jpg?id=OA2702648\",\"datePublished\":\"2026-06-15T12:50:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS653209\\\/Elanco_Logo.jpg?id=OA2702648\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS653209\\\/Elanco_Logo.jpg?id=OA2702648\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\\\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/","og_locale":"en_US","og_type":"article","og_title":"Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs - Market Newsdesk","og_description":"PR Newswire TruCan Ultra Lyme-L4\u00a0is the first and only 1\/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine minimizes &#8220;pokes&#8221; supporting comfortable wellness visits for pets Features proprietary\u00a0PureFil\u2122 Technology, designed to reduce vaccination reactions associated with unwanted proteini,ii,iii Product expected to begin shipping in the next 30 days INDIANAPOLIS, June 15, 2026 \/PRNewswire\/ &#8212; Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) approval of\u00a0TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vaccines. This milestone marks the introduction of the first and only 1\/2 mL combination vaccine designed to protect dogs against both Lyme &hellip; Continue reading \"Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-15T12:50:16+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS653209\/Elanco_Logo.jpg?id=OA2702648","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs","datePublished":"2026-06-15T12:50:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/"},"wordCount":868,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS653209\/Elanco_Logo.jpg?id=OA2702648","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/","name":"Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS653209\/Elanco_Logo.jpg?id=OA2702648","datePublished":"2026-06-15T12:50:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS653209\/Elanco_Logo.jpg?id=OA2702648","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS653209\/Elanco_Logo.jpg?id=OA2702648"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combination-vaccine-for-lyme-and-leptospirosis-for-dogs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Elanco Announces USDA Approval of TruCan\u2122 Ultra Lyme-L4, the First and Only 1\/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=972078"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972078\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=972078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=972078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=972078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}